Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Decreased by Millennium Management LLC

Millennium Management LLC lessened its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 276,578 shares of the company's stock after selling 21,857 shares during the period. Millennium Management LLC owned approximately 0.22% of Vaxcyte worth $22,641,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PCVX. Capital Research Global Investors increased its holdings in shares of Vaxcyte by 26.8% in the 4th quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock worth $508,393,000 after acquiring an additional 1,312,302 shares during the period. Norges Bank acquired a new stake in shares of Vaxcyte in the 4th quarter worth about $90,069,000. Vanguard Group Inc. increased its holdings in shares of Vaxcyte by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock worth $979,184,000 after acquiring an additional 521,204 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Vaxcyte in the 4th quarter worth about $39,846,000. Finally, Hood River Capital Management LLC acquired a new stake in shares of Vaxcyte in the 4th quarter worth about $32,862,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on PCVX shares. Needham & Company LLC reissued a "buy" rating and set a $90.00 target price on shares of Vaxcyte in a research note on Tuesday, April 8th. Cantor Fitzgerald started coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating on the stock. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Bank of America lowered their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Guggenheim reissued a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Vaxcyte has a consensus rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded down $1.41 during trading hours on Monday, hitting $32.54. 1,763,863 shares of the company's stock traded hands, compared to its average volume of 1,371,448. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The company's fifty day simple moving average is $37.66 and its two-hundred day simple moving average is $68.44. The company has a market cap of $4.20 billion, a price-to-earnings ratio of -7.07 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the prior year, the company posted ($0.85) EPS. On average, analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Activity

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.